Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.31 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234663 | 0.91 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL20920359 | 0.88 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL24854325 | 0.88 | HRH3 (0.33) | HSD11B1 | |
| SCHEMBL10223661 | 0.86 | ATM (0.39) | HSD11B1ATM | |
| SCHEMBL10223663 | 0.86 | ATM (0.39) | HSD11B1ATM | |
| SCHEMBL6582513 | 0.86 | ATM (0.39) | HSD11B1ATM | |
| SCHEMBL24854083 | 0.83 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL24856352 | 0.82 | — | — | |
| SCHEMBL21935524 | 0.82 | NPC1 (0.32) | HSD11B1LMNA | |
| SCHEMBL12359974 | 0.81 | HSD11B1 (0.33) | HSD11B1KCNQ3KCNQ2KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11786575-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20090048297-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | HSD11B1 1213/4885ATM 3544/4885KCNQ3 1765/4885 |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | CBR3, CBR1, GRHPR | HSD11B1 846/4885ATM 4081/4885KCNQ3 1124/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | HSD11B1 4483/4885ATM 3214/4885KCNQ3 4406/4885 |
| US-11786575-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | HSD11B1 1836/4885ATM 4880/4885KCNQ3 3730/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | HSD11B1 1341/4885ATM 2352/4885KCNQ3 932/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | HSD11B1 381/4885ATM 756/4885KCNQ3 4670/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | HSD11B1 2067/4885ATM 4765/4885KCNQ3 60/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | HSD11B1 2746/4885ATM 2788/4885KCNQ3 1657/4885 |
| US-20090048297-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | HSD11B1 2118/4885ATM 4869/4885KCNQ3 2129/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | HSD11B1 1512/4885ATM 315/4885KCNQ3 3614/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | HSD11B1 1008/4885ATM 775/4885KCNQ3 1850/4885 |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | HSPBP1, HSF1, HSPH1 | HSD11B1 2343/4885ATM 3704/4885KCNQ3 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.